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The combined disk assay has been used for detection of metallo--lactamase-producing isolates. We have
observed that the size of inhibition zones produced by many -lactam/metallo--lactamase inhibitor (IMBL)
combinations may differ depending on the way that the combined disks were prepared. Among the 10
-lactam/IMBL combinations tested, only the imipenem/EDTA combination produced similar results.
Metallo--lactamase (MBL)-producing isolates have been
increasingly reported in many geographic regions (12). Due to
the ability of MBL-producing isolates to spread and to hydro-
lyze most -lactam agents, accurate detection of this resistance
phenotype by routine laboratories is essential to initiate ade-
quate empirical therapy and to implement proper infection
control practices.
There are no current Clinical Laboratory Standards Institute
(CLSI) guidelines for screening bacterial isolates for acquired
MBL production. Several phenotypic tests have been devel-
oped for MBL detection, such as the MBL Etest (AB Biodisk,
Solna, Sweden) (9, 14, 18), double-disk synergy tests (1, 7, 9),
combined disk (CD) assay (14, 15, 20), microdilution (11), and
the Hodge test (7). All of these tests are based upon the ability
of chelating agents, EDTA and thiol-based compounds, to
inhibit the MBL activity.
The combined disk assay employs a -lactam disk, usually a
carbapenem or ceftazidime, to which an MBL inhibitor (IMBL) is
added. The results are further compared with the inhibition
zones produced by the corresponding -lactam agent alone.
Due to its objective interpretation, this test has been consid-
ered a good phenotypic resource (5). However, the incorpora-
tion of IMBL into the ceftazidime or imipenem disks has not
been standardized yet. Different studies have either (i) added
the IMBL solution directly on the -lactam disk already placed
on the agar plate (AD) (6, 20) or (ii) previously prepared the
disks (PP) (5, 19), which are dried at ambient temperature and
stored at 4°C or 20°C for future use (20). Therefore, it is not
known if results obtained by the combined disk assay using
distinct IMBL incorporations are different. Upon screening for
MBL-producing isolates in our laboratory, we realized we
could have obtained different results for some isolates, de-
pending on the way that IMBLs were added to -lactam disks.
Thus, we have designed a study to verify inhibition zone results
for (i) -lactam/IMBL disks previously prepared, dried, and
stored (PP) and (ii) -lactam/IMBL disks prepared by adding
the IMBL solution after placing the -lactam disk on a Muel-
ler-Hinton (MH) agar plate (AD). We believed it was impor-
tant to investigate whether AD and PP would display identical
inhibition zone results, since screening of suspicious MBL-
producing isolates by CD is directly influenced by the size of
inhibition zones.
The isolates evaluated in this study are described in Table 1.
Only genetically unrelated MBL producers were selected. A
total of five IMP-1 producers, one of each species tested, were
selected (Pseudomonas aeruginosa, Acinetobacter sp., Serratia
marcescens, Enterobacter cloacae, and Klebsiella pneumoniae).
Other isolates included two VIM-1-producing E. cloacae strains,
one SPM-1-producing P. aeruginosa strain, one GIM-1-produc-
ing P. aeruginosa strain, and one SIM-1-producing Acineto-
bacter baumannii strain.
The IMBLs were purchased from Sigma (Steinheim, Ger-
many), except for mercaptoethanol, which was obtained from
Gibco (New York, NY). The IMBL solutions tested were 100
mM EDTA, 1.4 mM mercaptopropionic acid (MPA), 1.2 mM
mercaptoacetic acid (MAC), 55 mM mercaptoethanol (MET),
and 8 mM phenanthroline (PHEN). The size of the inhibition
zones produced by -lactam disks containing 10 l of each
IMBL solution was assessed.
The phenotypic tests were performed by following the CLSI
recommendations for the disk diffusion method. Briefly, a 0.5
McFarland bacterial suspension was inoculated on an MH agar
plate (Oxoid, Basingstoke, England). For the AD combined
disk assay, ceftazidime and imipenem disks were first placed on
the inoculated MH plates, and 10 l of each inhibitor solution
was directly added to the disks. For the PP combined disk
assay, 10 l of the IMBL solutions was previously incorporated
into ceftazidime and imipenem disks, which were immediately
dried at room temperature and stored overnight at20°C. The
-lactam/IMBL disks were then placed on MH agar plates
inoculated previously with the test strain. After overnight in-
cubation at 35°C, the size of the combined disk inhibition zone
was measured and compared to that displayed by the -lactam
disk itself for both methodologies (AD and PP). Since there is
no general consensus about which breakpoints should be used
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to classify a bacterial isolate as an MBL producer and we do
not know which breakpoint would work better under the tested
conditions, we only present results of mean inhibition zones of
MBL-producing isolates. Thus, this study was not designed to
determine which one (AD or PP) would be the best test to
detect MBL-producing isolates.
For each of the 10 -lactam/IMBL combinations, a total of
20 experiments were performed (10 PP and 10 AD), leading to
200 observations. The results of this study are shown in Table
2. AD and PP presented different results for MBL detection
according to the -lactam/IMBL combination employed.
Among the MBL-producing isolates, larger inhibition zones
were observed for the AD test, except for imipenem/EDTA
(mean of AD and PP, 9.0 mm) and imipenem/MAC (mean of
AD, 4.0 mm; mean of PP, 5.0 mm). The greatest discrepancy
between AD and PP was noticed for the ceftazidime/MAC
combination (15.9 mm versus 8.2 mm, respectively), followed
by imipenem/MET (5.0 mm versus 0.0 mm, respectively) (Ta-
ble 2).
We have noticed that the mean size of inhibition zones
produced by combining EDTA and imipenem was the same for
both AD and PP. This finding is significant, since differences in
the preparation of the disks would not have influenced MBL
detection. In this manner, studies that have employed this
combination might have their final results compared.
On the other hand, we have demonstrated that the sizes of
inhibition zones produced by many -lactam/IMBL combina-
tions differ after incubation, depending on the way the com-
bined disks were prepared, with the AD test usually producing
larger inhibition zones. These results might reflect, in part, a
reduced ability of PP to keep the IMBL volumes dispensed
into the -lactams during the process of disk preparation and
20°C storage. For this reason, a given isolate may not be
equally classified under the same category (MBL producer or
non-MBL producer) by AD and PP CD assay when phenotypic
MBL detection is being performed. Since the imipenem/
EDTA combinations had produced comparable results inde-
pendent of the EDTA incorporation into the -lactam disks,
the volatility of thiol-based compounds could be argued to be
one of the possible reasons for having discrepant results be-
tween the AD and PP tests. However, the incorporation of
EDTA into ceftazidime disks also produced distinct results,
implying that factors other than volatility are involved.
This study did not intend to select the best CD methodology
for detecting MBL-producing isolates but calls attention to the
fact that discordant results might occur. We believe both AD
and PP may be used for MBL detection, but interpretation of
results may vary according to the -lactam/IMBL selected. It
should be noted that the selection of an appropriate break-
point for screening MBL-producing isolates is directly influ-
enced by the -lactam/IMBL combination and by the way
IMBLs are incorporated into the -lactam disks. Thus, stan-
dardization of either AD or PP testing of additional IMBL
concentrations may be necessary for intra- and interlaboratory
comparison. In addition, the employed methodology for prep-
aration of the -lactam/IMBL combination should be discrim-
inated in future studies to help interpretation and comparison
of their results.
In comparison to the other MBL tests, the disk has been
reported to be a simple, inexpensive phenotypic resource for
detection of MBL that could be easily incorporated into the
routine of clinical laboratories (15). Since commercial prepa-
rations of combined disks are not available, further studies
standardizing the performance and interpretation of the CD
assay are of crucial importance to guarantee its intra- and
interlaboratory reproducibility.
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